- Home
- TFX vs MDGL Comparison
TFX vs MDGL Comparison
Compare TFX & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFX
- MDGL
- Stock Information
- Founded
- TFX 1943
- MDGL 2011
- Country
- TFX United States
- MDGL United States
- Employees
- TFX N/A
- MDGL N/A
- Industry
- TFX Medical/Dental Instruments
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- TFX Health Care
- MDGL Health Care
- Exchange
- TFX Nasdaq
- MDGL Nasdaq
- Market Cap
- TFX 5.5B
- MDGL 6.1B
- IPO Year
- TFX N/A
- MDGL N/A
- Fundamental
- Price
- TFX $124.92
- MDGL $427.82
- Analyst Decision
- TFX Hold
- MDGL Strong Buy
- Analyst Count
- TFX 9
- MDGL 10
- Target Price
- TFX $141.57
- MDGL $485.78
- AVG Volume (30 Days)
- TFX 609.6K
- MDGL 294.9K
- Earning Date
- TFX 10-30-2025
- MDGL 10-30-2025
- Dividend Yield
- TFX 1.09%
- MDGL N/A
- EPS Growth
- TFX N/A
- MDGL N/A
- EPS
- TFX 4.18
- MDGL N/A
- Revenue
- TFX $3,041,342,000.00
- MDGL $515,547,000.00
- Revenue This Year
- TFX $10.42
- MDGL $394.08
- Revenue Next Year
- TFX $10.58
- MDGL $61.80
- P/E Ratio
- TFX $29.90
- MDGL N/A
- Revenue Growth
- TFX 1.11
- MDGL 3421.98
- 52 Week Low
- TFX $108.90
- MDGL $200.63
- 52 Week High
- TFX $241.41
- MDGL $463.63
- Technical
- Relative Strength Index (RSI)
- TFX 49.45
- MDGL 52.29
- Support Level
- TFX $126.19
- MDGL $433.03
- Resistance Level
- TFX $131.80
- MDGL $463.63
- Average True Range (ATR)
- TFX 3.75
- MDGL 14.71
- MACD
- TFX 0.32
- MDGL -3.96
- Stochastic Oscillator
- TFX 56.04
- MDGL 27.22
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.